Summary
EIDP, Inc. (CTA-PB) reported a 17% increase in third-quarter sales, reaching $7.0 billion, driven primarily by a 14% rise in sales volume across all geographic regions and product markets. This growth was supported by global economic recovery, particularly in emerging markets, which saw a 22% sales increase. Despite strong top-line performance, net income attributable to DuPont declined to $367 million from $409 million in the prior year, mainly due to reduced income from the Pharmaceuticals segment following patent expirations for key drugs like Cozaar®/Hyzaar®. For the nine-month period, net sales grew by 22% to $24.1 billion. The company continues to focus on productivity and cost-cutting initiatives to maintain a strong balance sheet and capital productivity. Strategic investments in new product development for agriculture, photovoltaics, and alternative energy remain a priority. While facing increased costs for raw materials, energy, and freight, the company is actively managing these pressures through price adjustments and efficiency improvements. The company has also issued new debt, increasing its total debt to $12.4 billion, while maintaining a significant cash and marketable securities balance of $6.0 billion.
Financial Highlights
49 data points| Revenue | $7.00B |
| R&D Expenses | $409.00M |
| SG&A Expenses | $782.00M |
| Operating Expenses | $6.74B |
| Operating Income | $763.00M |
| Interest Expense | $103.00M |
| Net Income | $369.00M |
| EPS (Basic) | $0.40 |
| EPS (Diluted) | $0.40 |
| Shares Outstanding (Basic) | 908.37M |
| Shares Outstanding (Diluted) | 918.50M |
Key Highlights
- 1Total consolidated sales for the third quarter of 2010 increased by 17% to $7.0 billion, driven by a 14% increase in sales volume.
- 2Sales in emerging markets showed robust growth, up 22% in the third quarter and accounting for 31% of total sales year-to-date.
- 3Net income attributable to DuPont decreased by 10% to $367 million in the third quarter, primarily due to lower income from the Pharmaceuticals segment resulting from patent expirations.
- 4Cost of Goods Sold (COGS) as a percentage of net sales increased by 2 percentage points to 78% in Q3 2010, attributed to higher raw material, energy, and freight costs.
- 5Research and Development (R&D) expenses increased by approximately 22% to $409 million in Q3 2010, reflecting continued investment in growth areas.
- 6The company maintains a strong liquidity position with $6.0 billion in cash and marketable securities and access to approximately $2.5 billion in unused credit lines.
- 7Free cash flow for the nine months ended September 30, 2010, was a negative $864 million, a significant decrease from the prior year's negative $67 million, although the company expects a positive full-year free cash flow of $1.7 billion.